Mefe and Slam: Gay Community Faces Resurgence of HIV Risk via IV Drug Use

Mefe and Slam: The 80s Ghost Returns to the Lgtb World

There is a term that until recently sounded like laboratory jargon but is now circulating with alarm in public health discussions: mefe. Mefedrona, a synthetic stimulant sold as a cheap cocaine substitute but laced with unknown substances, has infiltrated leisure circuits where intravenous use—known as slam—is no longer an exception but a recurrent practice. The diagnosis is stark: scenes thought to be overcome since the 1980s, when AIDS ravaged without anyone knowing its cause, are resurfacing.

The concern is not abstract. Those who have witnessed it firsthand speak of people who started injecting at home, without a party context, and ended up in a spiral of dependency and physical deterioration. The profile breaks the stereotype of the marginal consumer: successful professionals, lawyers with bright careers, people who seemingly had everything. The problem is that addiction does not distinguish by paychecks.

What is mefedrona and why is it called mefe

Mefedrona is a synthetic stimulant that acts similarly to cocaine but at a much lower cost in the illegal market. Hence its expansion: where a considerable amount was once needed for recreational consumption, now only a fraction suffices. This economic accessibility is, according to those tracking the phenomenon, the key to its rapid spread among profiles not considered at risk.

The added problem is adulteration. Without health controls, each batch may contain different mixtures: stimulants, depressants, opioids. The consumer does not know what they are injecting. And when the route is intravenous, the margin for error narrows to almost nothing.

Slam: when intravenous use ceases to be marginal

Slam or slamming is the practice of injecting drugs, and in the circuits where it has been documented, it is associated with prolonged sens sessions, sometimes lasting several days. It is not a new phenomenon, but its normalization in certain environments is. What was previously associated with terminal junkies now infiltrates dating apps and private parties where the boundary between leisure and pathology blurs.

Some argue that the problem is being overemphasized and that drug use crosses all strata and orientations, not just one community. It is a reasonable argument. But firsthand testimonies point to a pattern: people who start out of curiosity, who do not consider themselves addicts, and who within months lose control over frequency and dosage.

The Ghost of AIDS and Immunodeficiency

The comparison with the 1980s is not rhetorical. Shared drug injection was one of the main vectors for HIV transmission in that decade, before effective treatments existed. For this route to reappear, in a context of uncontrolled consumption and lack of information, triggers all health alarms. You do not need to be an epidemiologist to see the connection.

The question is whether authorities are doing anything. The circulating answer is that not enough: publicly funded guidelines that, according to some readings, end up normalizing risky practices rather than discouraging them. The debate between harm reduction and zero tolerance approaches is back on the table.

Profiles Breaking the Consumer Stereotype

One of the most repeated testimonies is that of a top-tier lawyer who started injecting alone, without a party context, and ended up attempting suicide. He survived after agonizing for two days on the floor, miraculously attended. His professional circle never suspected anything until it was too late. Recovery, when it comes, leaves scars: isolation, broken relationships, truncated careers.

This case is not unique. What emerges is a pattern of solitary, shameful consumption that does not fit the public image of the addict. And because of this, it takes longer to detect and treat.

Social Context: From Euphoria to Antiestéticar

The conversation quickly shifts to the broader framework. Some view the phenomenon as a symptom of a society that has abandoned order, law, and respect, and is now reaping the consequences in the form of generalized deterioration. It is a catastrophist reading, but it connects with a diffuse unease that goes beyond drugs.

Others point to the responsibility of health authorities, urging them to take control before the situation spirals out of hand. The dominant sensation is that we are arriving late, as always, and that measures will come when the problem is already entrenched.

What to Expect in the Short Term

With available data, the most likely scenario is that consumption will continue to spread while there is no coordinated response. Mefedrona is cheap, easy to produce, and difficult to detect in routine checks. Slam, for its part, requires no major infrastructure: a syringe and a dose suffice.

The cautious prediction is that the problem will become more visible in the coming months, as serious cases in emergency rooms increase and the silence around a practice that remains taboo even within the environments where it occurs is broken.